iA Global Asset Management Inc. Decreases Stake in United Therapeutics Corporation $UTHR

iA Global Asset Management Inc. cut its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 53.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 298 shares of the biotechnology company’s stock after selling 349 shares during the quarter. iA Global Asset Management Inc.’s holdings in United Therapeutics were worth $86,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in UTHR. Nuveen LLC acquired a new position in United Therapeutics during the first quarter worth about $83,533,000. Amundi lifted its position in United Therapeutics by 198.8% during the first quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock worth $107,635,000 after buying an additional 232,988 shares during the period. Assetmark Inc. grew its holdings in United Therapeutics by 38.1% in the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after purchasing an additional 197,384 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in United Therapeutics during the second quarter worth about $55,746,000. Finally, Acadian Asset Management LLC increased its stake in United Therapeutics by 1,657.8% during the first quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company’s stock worth $55,217,000 after acquiring an additional 169,010 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of several research analyst reports. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Wednesday, October 29th. HC Wainwright upped their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Morgan Stanley set a $447.00 price target on United Therapeutics in a research note on Wednesday, October 29th. Weiss Ratings restated a “hold (c+)” rating on shares of United Therapeutics in a research note on Wednesday, October 8th. Finally, Oppenheimer upped their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $501.90.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 394,935 shares of company stock valued at $164,274,337 over the last ninety days. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Trading Down 0.3%

NASDAQ UTHR opened at $437.33 on Wednesday. The company’s fifty day simple moving average is $415.30 and its 200-day simple moving average is $340.89. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $479.50. The stock has a market cap of $18.83 billion, a P/E ratio of 16.57, a PEG ratio of 4.96 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same period in the previous year, the company posted $6.39 earnings per share. The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. On average, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.